Silvant Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.13M | Buy |
4,241
+265
| +7% | +$127K | 0.06% | 146 |
|
|
2026
Q1 | $1.95M | Buy |
3,976
+367
| +10% | +$199K | 0.07% | 133 |
|
|
2025
Q4 | $2.09M | Buy |
3,609
+17
| +0.5% | +$9.61K | 0.07% | 132 |
|
|
2025
Q3 | $1.74M | Buy |
3,592
+378
| +12% | +$176K | 0.06% | 137 |
|
|
2025
Q2 | $1.3M | Sell |
3,214
-56
| -2% | -$23.4K | 0.05% | 145 |
|
|
2025
Q1 | $1.63M | Sell |
3,270
-1,903
| -37% | -$1.03M | 0.07% | 133 |
|
|
2024
Q4 | $2.69M | Sell |
5,173
-555
| -10% | -$305K | 0.11% | 110 |
|
|
2024
Q3 | $3.55M | Sell |
5,728
-395
| -6% | -$234K | 0.16% | 87 |
|
|
2024
Q2 | $3.39M | Sell |
6,123
-40
| -0.6% | -$22.9K | 0.15% | 91 |
|
|
2024
Q1 | $3.58M | Sell |
6,163
-2,289
| -27% | -$1.28M | 0.17% | 84 |
|
|
2023
Q4 | $4.49M | Sell |
8,452
-1,561
| -16% | -$756K | 0.24% | 64 |
|
|
2023
Q3 | $5.07M | Sell |
10,013
-3,356
| -25% | -$1.79M | 0.31% | 51 |
|
|
2023
Q2 | $6.98M | Sell |
13,369
-816
| -6% | -$440K | 0.39% | 39 |
|
|
2023
Q1 | $8.18M | Sell |
14,185
-2,113
| -13% | -$1.19M | 0.53% | 33 |
|
|
2022
Q4 | $8.98M | Buy |
16,298
+41
| +0.3% | +$21.7K | 0.64% | 29 |
|
|
2022
Q3 | $8.25M | Sell |
16,257
-141
| -0.9% | -$78.9K | 0.56% | 30 |
|
|
2022
Q2 | $8.91M | Sell |
16,398
-182
| -1% | -$100K | 2.16% | 8 |
|
|
2022
Q1 | $9.8M | Sell |
16,580
-1,268
| -7% | -$728K | 1.87% | 9 |
|
|
2021
Q4 | $11.9M | Sell |
17,848
-1,007
| -5% | -$629K | 2.04% | 8 |
|
|
2021
Q3 | $10.8M | Sell |
18,855
-2,055
| -10% | -$1.13M | 1.92% | 10 |
|
|
2021
Q2 | $10.6M | Sell |
20,910
-430
| -2% | -$203K | 1.66% | 11 |
|
|
2021
Q1 | $9.74M | Sell |
21,340
-116
| -0.5% | -$55.4K | 1.66% | 10 |
|
|
2020
Q4 | $10M | Sell |
21,456
-133
| -0.6% | -$62.4K | 1.71% | 9 |
|
|
2020
Q3 | $9.54M | Sell |
21,589
-1,484
| -6% | -$613K | 1.78% | 10 |
|
|
2020
Q2 | $8.37M | Sell |
23,073
-357
| -2% | -$120K | 1.5% | 11 |
|
|
2020
Q1 | $6.65M | Sell |
23,430
-110
| -0.5% | -$34.7K | 1.45% | 13 |
|
|
2019
Q4 | $7.65M | Sell |
23,540
-157
| -0.7% | -$47.6K | 1.4% | 15 |
|
|
2019
Q3 | $6.91M | Sell |
23,697
-890
| -4% | -$255K | 1.37% | 14 |
|
|
2019
Q2 | $7.22M | Sell |
24,587
-788
| -3% | -$217K | 1.29% | 18 |
|
|
2019
Q1 | $6.95M | Sell |
25,375
-229
| -0.9% | -$57K | 1.25% | 16 |
|
|
2018
Q4 | $5.73M | Sell |
25,604
-12,791
| -33% | -$3M | 1.15% | 19 |
|
|
2018
Q3 | $9.38M | Sell |
38,395
-276
| -0.7% | -$63.5K | 1.16% | 16 |
|
|
2018
Q2 | $8.02M | Buy |
38,671
+491
| +1% | +$104K | 0.99% | 21 |
|
|
2018
Q1 | $7.89M | Buy |
+38,180
| New | +$8.01M | 1.01% | 19 |
|
Other funds holding TMO
Silvant Capital Management's TMO Position: Q2 2026 in Review
Silvant Capital Management increased its Thermo Fisher Scientific (TMO) stake by 6.7% in Q2 2026, buying an estimated $127K and bringing the position to 4,241 shares worth $2.13M. The position accounts for 0.06% of the portfolio, ranked #146.
Silvant Capital Management first reported a position in TMO in Q1 2018 and has held it in 34 quarters since. The position peaked at $11.9M in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Silvant Capital Management held 4,241 shares of Thermo Fisher Scientific worth $2.13M as of Q2 2026.
- Silvant Capital Management bought 265 Thermo Fisher Scientific shares in Q2 2026, an estimated $127K.
- Thermo Fisher Scientific made up 0.06% of Silvant Capital Management's portfolio in Q2 2026, its #146 holding.
- Silvant Capital Management first reported a position in Thermo Fisher Scientific in Q1 2018 and has held it in 34 quarters since.
- Silvant Capital Management's Thermo Fisher Scientific position peaked at $11.9M in Q4 2021.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.